January 23, 2017 5:04 PM ET


Company Overview of Eagle Pharmaceuticals, Inc.

Company Overview

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; Ryanodex injectable suspension for the treatment of malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for the treatment of breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and diclofenac-misoprostol. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid; EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocyt...

50 Tice Boulevard

Suite 315

Woodcliff Lake, NJ 07677

United States

Founded in 2007

67 Employees



Key Executives for Eagle Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 56
Total Annual Compensation: $874.2K
Chief Financial Officer
Age: 63
Total Annual Compensation: $449.8K
Chief Scientific Officer and Executive Vice President
Age: 57
Total Annual Compensation: $464.8K
Chief Medical Officer and Executive Vice President
Age: 55
Total Annual Compensation: $462.8K
Compensation as of Fiscal Year 2015.

Eagle Pharmaceuticals, Inc. Key Developments

Eagle Pharmaceuticals, Inc. Announces Executive Changes

On January 2, 2017, in connection with his appointment as President and Chief Commercial Officer of Eagle Pharmaceuticals, Inc., or the Company, David Pernock resigned from the board of directors of the Company, or the Board, (including his position as a member of the Board's Nominating and Corporate Governance Committee). In addition, in connection with Mr. Pernock's appointment, Scott Tarriff resigned from his position as President of the Company, effective January 2, 2017. Mr. Tarriff will continue to serve as the Company's Chief Executive Officer and as a member of the Board.

Eagle Pharmaceuticals, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-11-2017 11:00 AM

Eagle Pharmaceuticals, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-11-2017 11:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: David E. Riggs, Chief Financial Officer, Scott L. Tarriff, Chief Executive Officer and Director.

Eagle Pharmaceuticals, Inc. Submits New Drug Application for its Novel Pemetrexed Drug Product

Eagle Pharmaceuticals, Inc. announced that the 505(b)(2) New Drug Application (NDA) for its novel pemetrexed drug product has been submitted to the U.S. Food and Drug Administration (FDA). This 505(b)(2) NDA requests FDA approval of Eagle’s ready-to-dilute (RTD) Pemetrexed Injection product for the treatment of Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer, and Mesothelioma (in combination with cisplatin). Eagle’s RTD Pemetrexed Injection product is administered as an IV infusion.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

November 11, 2016
Arsia Therapeutics, Inc.
August 9, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Eagle Pharmaceuticals, Inc., please visit www.eagleus.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.